ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Tsumura & Co.

Business Summary

Tsumura & Co. engages in the manufacture and sale of pharmaceutical products. It manufactures and sells Kampo medicine, a traditional form of medicine in Japan. It is also involved in the procurement, production, processing, and storage of botanical raw materials; production and sale of Kampo extract intermediates; and provision of logistics, storage, distribution, and materials handling services. Its products include Chujoto, L'amour, Tsumura-Kampo Kakkonto, Tsumura-Kampo Otsujito, and Tsumura-Kampo Orengedokuto. The company was founded by Jusha Tsumura on April 10, 1893 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2022 JPYUSD
Gross Profit66,465M591.46M
Operating income22,377M199.13M
Income before tax25,563M227.48M
Net income18,836M167.62M
Diluted EPS246.192.19
Dividends Per Share640.56
Total Assets350,981M2,891.70M
Total liabilities92,869M765.14M
Total equity239,770M1,975.44M
Operating cash flow21,314M189.67M
Currency in JPYCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 117,882M 120,906M 123,248M 116,413M 129,546M
Gross Profit 68,275M 71,456M 72,500M 60,464M 66,465M
Operating income 17,051M 18,521M 18,877M 19,383M 22,377M
Income before tax 20,284M 19,897M 19,223M 20,456M 25,563M
Net income 14,505M 14,594M 13,765M 15,332M 18,836M
EBITDA 23,208M 24,883M 25,283M 27,998M 31,566M
Diluted EPS 200.54 190.86 179.96 200.39 246.19
Dividends Per Share 64 64 64 64 64
Total Assets 292,379M 287,322M 313,537M 319,063M 350,981M
Total liabilities 95,845M 81,178M 99,537M 85,892M 92,869M
Total equity 193,600M 201,817M 205,378M 217,787M 239,770M
Operating cash flow 21,066M 5,450M 18,191M 16,102M 21,314M
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 1,063.60M 1,090.27M 1,133.56M 1,097.64M 1,152.82M
Gross Profit 616.02M 644.35M 666.81M 570.10M 591.46M
Operating income 153.84M 167.01M 173.62M 182.75M 199.13M
Income before tax 183.01M 179.42M 176.80M 192.87M 227.48M
Net income 130.87M 131.60M 126.60M 144.56M 167.62M
EBITDA 209.39M 224.38M 232.53M 263.98M 280.90M
Diluted EPS 1.80 1.72 1.65 1.88 2.19
Dividends Per Share 0.57 0.57 0.58 0.60 0.56
Total Assets 2,749.21M 2,595.85M 2,904.33M 2,887.44M 2,891.70M
Total liabilities 901.22M 733.41M 922.02M 777.30M 765.14M
Total equity 1,820.40M 1,823.34M 1,902.44M 1,970.92M 1,975.44M
Operating cash flow 190.07M 49.14M 167.31M 151.82M 189.67M

Valuation Measures

Mar 2022
Operating margin17.27%
Profit margin14.54%

Key executives

  • President, CEO & Representative Director: Terukazu Kato
  • COO, Director & Managing Executive Officer: Shin Adachi
  • CFO, Director & Managing Executive Officer: Muneki Handa
  • Executive Officer, GM-Kampo Research & Development: Akito Imada
  • Executive Officer, Manager-Legal & Compliance: Hiroshi Hoshi


  • Invesco Asset Management (Japan) Ltd. (11.9%)
  • Ping An Insurance (Group) Co. of China Ltd. (9.9%)
  • Marathon Asset Management Ltd. (6.0%)
  • Mitsubishi UFJ Financial Group, Inc. (3.5%)
  • Nomura Asset Management Co., Ltd. (2.5%)
  • Baillie Gifford & Co. (2.5%)
  • Tsumura & Co. Employee Stock Ownership Plan (2.3%)
  • Bright Ride Ltd. (2.2%)
  • The Vanguard Group, Inc. (2.1%)
  • Templeton Investment Counsel LLC (1.7%)

Contact Details

Related Companies

  • Pingcun (Shenzhen) Medical Ltd.
  • Ping An Tsumura Co., Ltd.
  • Tsumura Board Incentive Plan
  • Shenzhen Tsumura Medicine Co., Ltd.
  • Shanghai Tsumura Pharmaceuticals Co., Ltd.
  • Logitem Tsumura KK
  • Tsumura USA, Inc.
  • Tsumura & Co. Employee Stock Ownership Plan


    Last Updated on 26 Sep, 2022

    Discover the all new Nikkei Asia app

    • Take your reading anywhere with offline reading functions
    • Never miss a story with breaking news alerts
    • Customize your reading experience

    Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

    Celebrate our next chapter
    Free access for everyone - Sep. 30

    Find out more